(LOOTPRESS) – In the span of just a few days, the Food and Drug Administration approved two major cancer treatments — one for a rare genetic form of lung cancer, the other for aggressive bladder cancer.
For a state like West Virginia, where lung cancer rates are among the highest in the country and bladder cancer is more common than the national average, these announcements come with real implications for local patients and healthcare providers.
1. Hyrnuo (sevabertinib) – Targeted therapy for HER2-mutated lung cancer
On November 19, 2025, the FDA granted accelerated approval to Hyrnuo (sevabertinib) for adults with advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain mutations and who have already received prior systemic treatment.
Manufacturer: Bayer HealthCare Pharmaceuticals
Type: Oral tyrosine kinase inhibitor
Indication: HER2-mutated NSCLC after prior therapy
HER2 mutations represent a small but important subset of lung cancer. Until now, patients with this mutation had limited targeted options and typically faced poorer outcomes.
Availability timeline
Because Hyrnuo is an oral drug and Bayer had commercial supply ready ahead of approval, distribution to oncology pharmacies typically occurs within weeks. The larger delay usually comes from insurers updating coverage and prior-authorization criteria, a process that often takes one to three months.
Oncologists in West Virginia’s regional cancer centers should be able to begin prescribing Hyrnuo within the next few months, provided patients undergo the necessary biomarker testing and insurance approval.
Why this matters in West Virginia
This approval highlights the growing need for statewide access to comprehensive tumor biomarker testing.
2. Keytruda + Padcev combination – New option for muscle-invasive bladder cancer
On November 21, 2025, the FDA approved a perioperative (before and after surgery) combination therapy for adults with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, the long-time standard.
The combination pairs:
This regimen is now approved:
Clinical trials showed this approach reduces the risk of cancer progression or death by roughly 60% compared to surgery alone.
Availability timeline
Because both Keytruda and Padcev were already widely used for other bladder and urothelial cancer indications, this approval is a label expansion rather than a brand-new product launch. That means:
Why this matters in West Virginia
What these approvals mean for West Virginia healthcare
1. Greater need for biomarker testing
Both drugs rely on precision diagnostics:
West Virginia has struggled with access to advanced biomarker testing. Without improvements in insurance coverage and lab capacity, patients risk missing opportunities to qualify for these therapies.
2. Increased strain and coordination for rural cancer centers
These therapies demand:
Smaller hospitals may need to refer patients to larger centers in Charleston, Morgantown, Huntington, or out-of-state partners.
3. High cost and insurance hurdles
Targeted therapies and antibody-drug conjugates are extremely expensive.
For many West Virginians on Medicaid, Medicare, or PEIA, access will depend on:
4. Steps toward narrowing cancer-outcome gaps
West Virginia consistently ranks near the bottom in cancer survival.
These new therapies offer:
In a single week, the FDA approved:
For a state where lung and bladder cancer hit especially hard, these approvals offer meaningful new options — but only if testing, insurance coverage, and clinical capacity keep up.
